Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) April 30, 2014

Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial (PL1.003)

David Jacoby, James Rusche, Marco Iudicello, Stefania De Mercanti, Marinella Clerico, Marco Gibbin, Filomena Longo, Wenyan Miao, Myriam Rai, Antonio Piga, Massimo Pandolfo, Luca Durelli
First published April 9, 2014,
David Jacoby
4Repligen Waltham MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Rusche
6Repligen Corporation Waltham MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Iudicello
2Divisione Universitaria di Neurologia Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania De Mercanti
2Divisione Universitaria di Neurologia Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinella Clerico
2Divisione Universitaria di Neurologia Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Gibbin
2Divisione Universitaria di Neurologia Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filomena Longo
3Divisione Universitaria di Pediatria Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenyan Miao
5R&D Repligen Corp Waltham MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myriam Rai
1Brussels Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Piga
3Divisione Universitaria di Pediatria Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Pandolfo
7Universite Libre De Bruxelles Brussels Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Durelli
2Divisione Universitaria di Neurologia Torino Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial (PL1.003)
David Jacoby, James Rusche, Marco Iudicello, Stefania De Mercanti, Marinella Clerico, Marco Gibbin, Filomena Longo, Wenyan Miao, Myriam Rai, Antonio Piga, Massimo Pandolfo, Luca Durelli
Neurology Apr 2014, 82 (10 Supplement) PL1.003;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE Demonstrate oral histone deacetylase inhibitors increase frataxin expression in Friedreich’s ataxia (FRDA) patients at doses that can be safely administered. BACKGROUND In culture, histone deacetylase inhibitors (HDACi) increased FXN mRNA and protein expression in ex vivo treated patient blood cells. In vivo treatment using transgenic animal models for FRDA increased FXN mRNA and protein in target tissues and reduced disease related pathology. A 2-aminobenzamide HDACi (109/RG2833) was evaluated in nonclinical toxicology, pharmacology and safety studies to support use of this compound in FRDA patients. DESIGN/METHODS A Phase I clinical study to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered 109/RG2833 in 20 adults with FRDA was approved after national and hospital regulatory review. Four cohorts of 5 FRDA patients where Cohort 1 and 2 were open label, with single 30-120mg doses. Cohorts 3 and 4 were randomized, double blind, placebo controlled crossover studies. Cohort 3, a single 180mg or placebo dose; cohort 4, two 120mg or of placebo doses, 4 hours apart. Primary outcome was safety and pharmacodynamic response on HDAC inhibition and FXN mRNA and protein levels in patient blood cells. HDAC activity in patient PBMC was measured with a deacetylase assay using the Fluor-de-LysTM substrate. qRT-PCR and frataxin dipstick assays were used to measure FXN mRNA and protein respectively. RESULTS RG2833 was well tolerated with no limiting toxicities reported. We detected dose dependent suppression of deacetylase activity in the PBMC lysates from the RG2833 treated subjects. An average induction of 1.5-1.6 fold of FXN mRNA levels was observed in patients treated with 120-240mg doses. Small frataxin protein induction was observed in 3 patients with 180-240mg doses. CONCLUSIONS This study provides proof of principal for orally administered class I HDAC inhibitor as potential therapeutics for Friedreich’s ataxia. Study Supported by: Repligen Corporation, GoFAR and EFACTS

Disclosure: Dr. Jacoby has received personal compensation for activities with Repligen and BioMarin as an employee. Dr. Rusche has received personal compensation for activities with Repligen Corp. Dr. Rusche holds stock and/or stock options in Repligen Corp. which sponsored research in which Dr. Rusche was involved as an investigator. Dr. Rusche has received research support from Repligen Corp. Dr. Iudicello has nothing to disclose. Dr. De Mercanti has nothing to disclose. Dr. Clerico has nothing to disclose. Dr. Gibbin has nothing to disclose. Dr. Longo has nothing to disclose. Dr. Miao has received personal compensation for activities with Repligen. Dr. Miao holds stock and/or stock options in Repligen which sponsored research in which Dr. Miao was involved as an investigator. Dr. Rai has nothing to disclose. Dr. Piga has received personal compensation for activities with Repligen as a member of a Safety Committee Board. Dr. Pandolfo has received personal compensation for activities with Repligen and Apopharma. Dr. Pandolfo has received royalty payments from Athena Diagnostics. Dr. Pandolfo has received research support from Repligen. Dr. Durelli has received research support from Repligen Corp.

Wednesday, April 30 2014, 9:00 am-12:00 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise